Wacker Chemie

Polysilicon is the largest segment by asset intensity, with hyperpure polysilicon production sites in Burghausen, Germany and Charleston, Tennessee supplying solar-wafer manufacturers globally. The firm has disclosed that it supplies roughly half the solar-grade polysilicon market outside of China (per the firm's official communications, 2023). Revenues and margins in this division are structurally cyclical, tied to Chinese solar installation policy, global electricity prices, and wafer-inventory cycles.

Biosolutions is the smallest of the four operating divisions by revenue and capex but carries the highest margin profile. Deployment targets cyclodextrin and cysteine biotech capacity — fermentation-derived specialty products — rather than commoditized industrial biotech. Capital commitments tend to be sub-€100 million increments and are funded from group cash flow rather than discrete project-finance structures.

Semiconductor-grade polysilicon requires dramatically higher purity thresholds and commands a multiple on per-kilogram pricing relative to solar-grade. Wacker's March 2025 capex guidance explicitly weights purification capacity for semiconductor applications, reflecting the post-Chips Act onshoring demand signal. The investment logic shares the same base chemistry as solar polysilicon but serves a structurally different buyer set — global foundries — and carries less correlation to solar installation cycles.